Home

PB01 FOR INFLAMMATION & FIBROSIS

Paranta Biosciences is a clinical stage biopharmaceutical company focused on developing PB01 (recombinant human follistatin-288), a novel biotherapeutic for the treatment of inflammatory and fibrotic diseases.
Paranta’s current areas of focus for PB01 are:
•    Respiratory Diseases – with initial focus on cystic fibrosis (CF) lung disease;
•   Oncology – chemo resistant cancers, with initial focus on non-small cell lung cancer (NSCLC)

Leave a Reply